TX

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Fibroblast, EGFR, Warfarin necrosis, Risk, Communication, IL-6, Form, Diabetic foot ulcer, Conditional sentence, Patient, Research, Mouse, Gamma ray, Trial of the century, HDF, Hyperglycemia, Acceleration, Wound healing, Cytokine, Therapy, Cellular senescence, Interleukin, VEGF, Pharmaceutical industry

These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.

Key Points: 
  • These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
  • Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally.
  • FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
  • "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja.

Most Smoking Employees Gain Over Three Weeks of Paid Time Off Through Smoke Breaks According to New Study

Retrieved on: 
Thursday, April 4, 2024
Research, Telecommunications, Smoker, Smoking, Environment, Tobacco

The study underscores the importance of promoting productive breaks among employees that do not significantly disrupt the workday.

Key Points: 
  • The study underscores the importance of promoting productive breaks among employees that do not significantly disrupt the workday.
  • The study also showed that smoking at work exacerbates the difficulty of quitting, with over 60% of respondents citing workplace smoking as a barrier.
  • “The study revealed high smoking rates in industries such as retail, catering and leisure, IT and telecommunications, and healthcare.
  • To learn more about the global transformation of inspiring smokers to conscious enjoyment and explore smoke-free alternatives available across the US, visit www.nicokick.com .

North Texas Food Bank to Host Taste of the Cowboys Fundraiser

Retrieved on: 
Thursday, April 4, 2024
Star, Hunger, Child, Table, Cowboy, Taste, Future, Ford Center, Dallas Cowboys, Film industry

Dallas, TX, April 04, 2024 (GLOBE NEWSWIRE) -- The North Texas Food Bank (NTFB) and the Dallas Cowboys will host the 20th Annual Taste of the Cowboys fundraiser, presented by Ashley, on the field at Ford Center at The Star in Frisco – home of the Dallas Cowboys World Headquarters – on Friday, April 7, 2024.

Key Points: 
  • Dallas, TX, April 04, 2024 (GLOBE NEWSWIRE) -- The North Texas Food Bank (NTFB) and the Dallas Cowboys will host the 20th Annual Taste of the Cowboys fundraiser, presented by Ashley, on the field at Ford Center at The Star in Frisco – home of the Dallas Cowboys World Headquarters – on Friday, April 7, 2024.
  • The event will feature live entertainment by country star John Michael Montgomery and gourmet tailgate food stations from some of DFW’s favorite restaurants, led by Taste of the Cowboys Founding Chef, Kent Rathbun.
  • All proceeds from the Taste of the Cowboys provide critical funds to support the North Texas Food Bank’s Nourish the Future programs that directly target child hunger.
  • Last year’s Taste of the Cowboys event provided access to 1.5 million meals for children experiencing hunger to help address this need.

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Retrieved on: 
Thursday, April 4, 2024
Safety, CIIC, Abstract, HAE, Hereditary angioedema, Conference, Bradykinin receptor B2, Pharmaceutical industry

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Key Points: 
  • ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.
  • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations .

PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

Retrieved on: 
Thursday, April 4, 2024
Urology, SAN, Central Time, Physician, Health

SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.

Key Points: 
  • SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.
  • Members of PROCEPT BioRobotics’ management team presenting include:
    Barry Templin – Executive VP, Technology and Clinical Development
    Clinical perspectives will also be provided by the following physicians:
    A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/.
  • The webcast will be archived and available for replay for at least 90 days after the event.

Enhanced Capital Group Named to 13th Annual ImpactAssets 50 List

Retrieved on: 
Wednesday, April 3, 2024
PX, Database, P10, UN

DALLAS, April 03, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that its subsidiary Enhanced Capital Group LLC was named to the ImpactAssets 50™️ (IA 50) 2024 , a free publicly available, searchable database of global impact investment fund managers globally.

Key Points: 
  • DALLAS, April 03, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that its subsidiary Enhanced Capital Group LLC was named to the ImpactAssets 50™️ (IA 50) 2024 , a free publicly available, searchable database of global impact investment fund managers globally.
  • “P10 is proud of this recognition, and can speak firsthand to Enhanced Capital’s commitment to providing financing solutions to lower middle market borrowers that are seeking non-dilutive capital,” said Luke Sarsfield, P10 Chief Executive Officer.
  • The IA 50 received a record number of 343 applicants this year with a total of 155 firms selected, demonstrating the growing interest in and demand for the impact investment industry.
  • “As a private lender since 1999, Enhanced focuses on the lower middle market to provide market rate financing solutions to projects and businesses that meet our underwriting standards but lack access to traditional sources of capital,” said Michael Korengold, Enhanced Capital Chief Executive Officer.

LGI Homes Reports March and First Quarter 2024 Home Closings and Announces Date for First Quarter Earnings Conference Call

Retrieved on: 
Wednesday, April 3, 2024
Webcast, LGI Homes, Financial adviser

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 482 homes in March 2024.

Key Points: 
  • THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 482 homes in March 2024.
  • The Company closed 1,083 homes during the first quarter of 2024.
  • As of March 31, 2024, the Company had 120 active selling communities.
  • An archive of the webcast will be available for replay on the Company's website for one year from the date of the conference call.

BridgingApps® to Curate Apps for Sentara Health Plans Members with Special Health Care Needs

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Health, Smartphone, Database, Social, Caregiver, Patient, School, Hospital, Sentara Healthcare, Quality of life, Safety, Disability, Nursing

HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to provide expertly vetted lists of mobile device applications, or apps, to support its members who have special health care needs or disabilities.

Key Points: 
  • HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to provide expertly vetted lists of mobile device applications, or apps, to support its members who have special health care needs or disabilities.
  • Later this year, qualified Sentara Health Plans members will have access to a comprehensive list of curated apps recommended by BridgingApps Care Managers.
  • This will better equip members to manage their health decisions and develop important skill sets, ultimately improving their health and quality of life.
  • BridgingApps’ free App Search Tool, Search.BridgingApps.org , houses a database of apps trialed and reviewed by therapists, special education teachers, experts, and special needs users.

Intuitive Machines-led Moon RACER Team Awarded NASA Lunar Terrain Vehicle Contract to Support the Agency’s Artemis Campaign

Retrieved on: 
Wednesday, April 3, 2024
Machine, Longevity, Michelin, AVL, Artemis, Northrop Grumman, Lunar Terrain Vehicle, Architecture, Moon, NASA, Intuitive Machines, Grumman, Commercial Lunar Payload Services, Traction, LTV, Intuition, Communications satellite

HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- NASA has awarded Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines”) (“Company”) $30 million as a prime contractor to complete a Lunar Terrain Vehicle Services Feasibility Assessment.

Key Points: 
  • HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- NASA has awarded Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines”) (“Company”) $30 million as a prime contractor to complete a Lunar Terrain Vehicle Services Feasibility Assessment.
  • The contract tasks the Company’s global team with creating a feasibility roadmap to develop and deploy a Lunar Terrain Vehicle (“LTV”) on the Moon using Intuitive Machines’ Nova-D cargo-class lunar lander.
  • The Company believes the Moon RACER team is the most comprehensively equipped choice for delivering and deploying a lunar terrain vehicle that meets NASA requirements.
  • The Lunar Terrain Vehicle Services vehicle is a major element in returning humans to the lunar surface under NASA’s Artemis campaign and demonstrating continued American leadership in space exploration.

Crown Castle Announces First Quarter 2024 Earnings Conference Call Details   

Retrieved on: 
Wednesday, April 3, 2024
International, Webcast, Telephone number (mathematics), CCI

HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") plans to release its first quarter 2024 results on Wednesday, April 17, 2024, after the market closes.

Key Points: 
  • HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") plans to release its first quarter 2024 results on Wednesday, April 17, 2024, after the market closes.
  • In conjunction with the release, Crown Castle has scheduled a conference call for Wednesday, April 17, 2024, at 5:00 p.m. eastern time.
  • A listen only live audio webcast of the conference call, along with any supplemental materials, can be accessed on the Crown Castle website at https://investor.crowncastle.com .
  • All dial-in participants should ask to join the Crown Castle call.